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SUMMARY
Interleukin-2 (IL-2) is a fundamental cytokine that
controls proliferation and differentiation of T cells.
Here, we used high-resolution mass spectrometry
to generate a comprehensive and detailed map of
IL-2 protein phosphorylations in cytotoxic T cells
(CTL). The data revealed that Janus kinases (JAKs)
couple IL-2 receptors to the coordinated phos-
phorylation of transcription factors, regulators of
chromatin, mRNA translation, GTPases, vesicle traf-
ficking, and the actin and microtubule cytoskeleton.
We identified an IL-2-JAK-independent SRC family
Tyr-kinase-controlled signaling network that regu-
lates 10% of the CTL phosphoproteome, the pro-
duction of phosphatidylinositol (3,4,5)-trisphosphate
(PIP3), and the activity of the serine/threonine ki-
nase AKT. These data reveal a signaling framework
wherein IL-2-JAK-controlled pathways coordinate
with IL-2-independent networks of kinase activity
and provide a resource toward the further under-
standing of the networks of protein phosphorylation
that program CTL fate.
INTRODUCTION
Interleukin-2 (IL-2) directs the clonal expansion and differentia-
tion of CD4+ and CD8+ regulatory, effector, and memory T cell
populations. The IL-2 receptor (IL-2R) comprises IL-2Rb:IL-
2Rg heterodimers and CD25, the a chain, which confers high-
affinity binding of IL-2 to the receptor (Liao et al., 2013; O’Shea
et al., 2015). By coupling to the Janus family kinases JAK1 and
JAK3, the IL-2R controls the Tyr phosphorylation and activation
of Signal Transducer and Activator of Transcription 5 (STAT5)
transcription factors (Liao et al., 2013; O’Shea et al., 2015). The
biological importance of IL-2 has prompted interest in thera-
peutic manipulation of IL-2 signaling. Drugs to block IL-2-JAK
signaling are one approach to modulate adaptive immune
responses (O’Shea et al., 2015; Smith et al., 2016), but there
is increasing interest in using engineered cytokines or cytokine
antibodies to selectively modulate, rather than ablate, IL-2
signaling (Arenas-Ramirez et al., 2015; Mitra et al., 2015; Span-
gler et al., 2015).
Rational manipulation of IL-2 signaling is limited by the lack
of information about its full complexity. In particular, there is
growing recognition that IL-2 signaling extends beyond STATs
and includes signaling networks controlled by guanosine-50-
triphosphate hydrolases (GTPases) and lipid and serine/threo-
nine (Ser/Thr) kinases. IL-2-induced metabolic and transcrip-
tional programs are regulated by the Ser/Thr kinase, mammalian
target of rapamycin complex 1 (mTORC1) (Finlay et al., 2012;
Ray et al., 2015). IL-2 also drives the accumulation of active, gua-
nosine-50-triphosphate (GTP)-bound Ras GTPases and activa-
tion of the Raf-MAPK-ERK MAP kinase cascade (Liao et al.,
2013). Moreover, IL-2-maintained T cells accumulate phosphati-
dylinositol (3,4,5)-trisphosphate (PIP3) (Cornish et al., 2006), the
product of phosphatidylinositol 3-kinases (PI3K). This lipid binds
to the pleckstrin homology (PH) domain of the Ser/Thr kinase
AKT and coordinates its activation by phosphoinositide-depen-
dent protein kinase-1 (PDK1) (Najafov et al., 2012). The strength
and duration of AKT activity then direct T cell transcriptional pro-
grams that determine T cell fate (Macintyre et al., 2011).
In terms of the potential complexity of IL-2 signaling, IL-2-
maintained cytotoxic T cells (CTLs) express 250 protein ki-
nases and 120 protein phosphatases (Hukelmann et al., 2016).
However, the details of how IL-2R occupancy impacts protein
phosphorylation networks in CTLs are not mapped. Moreover,
while JAK1 and JAK3 are critical for IL-2 signal transduction, it
is not known if the IL-2R couples to Ser/Thr kinases solely by
JAK activation. Thus, IL-2 signaling has been reported to involve
SRC family kinases such as lymphocyte-specific protein tyrosine
kinase (LCK) (Hatakeyama et al., 1991; Horak et al., 1991; Ko-
bayashi et al., 1993) and FYN (Kobayashi et al., 1993). The impor-
tance of intrinsic SRC family kinase activity for antigen receptor
signaling in T cells is well documented (Chang et al., 2016; Nika
et al., 2010). In contrast, the role of SRC kinases in cytokine
signaling processes is not understood.
Accordingly, we used mass-spectrometry-based quantitative
phosphoproteomics to explore IL-2-controlled protein phos-
phorylation pathways in primary CD8+ effector cytotoxic T cells
where IL-2 directs the transcriptional programs that control pro-
liferation and effector functions. Our data mapped many previ-
ously unrecognized IL-2-controlledphosphorylations anduncov-
ered the diversity and intricacy of signaling pathways influenced
by IL-2. We also detected a network of IL-2-independent
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phosphorylations mediated by SRC family kinases in CTLs. This
JAK-independent signaling controlled PIP3 levels and AKT activ-
ity in CTLs. Our data provide a valuable resource of IL-2-medi-
ated phosphorylations and force a revision of the models of
IL-2 as a signaling switch for PIP3-AKT signaling. Additionally,
the data give new ideas for therapeutic modulation of key path-
ways that control CTL fate.
RESULTS
The IL-2-Regulated Phosphoproteome
To produce effector CTLs, antigen-primed P14 TCR transgenic
CD8+ T cells were clonally expanded in IL-2. For phosphoproteo-
mic work, we used SILAC and quantitative high-resolution mass
spectrometry following a protocol where CTLs were lysed and
digested with trypsin and phosphopeptides enriched by HILIC
fractionation followed by TiO2 affinity chromatography and anal-
ysis on an LTQ-Orbitrap Velos (Figure 1A). To examine IL-2-regu-
lated phosphorylations, CTLs were quiesced by 24 hr of IL-2
deprivation and then rechallenged with IL-2 for 15 min. One
complication of IL-2 deprivation experiments in primary non-
transformed T cells is that IL-2 is required for CTL survival and
for the expression of the high-affinity IL-2R complex. Accord-
ingly, we cultured IL-2-deprived CTLs in IL-12, which maintains
cell viability and supports expression of IL-2Rs and IL-2 respon-
siveness. The collective analysis of data from three biological
replicates of IL-2-deprived versus IL-2-stimulated CTLs identi-
fied 6,458 phosphorylations on 2,248 proteins (Figure 1B and
Table S1). The total number of phosphosites identified in the
individual biological replicates was similar (Figure 1C). In each
replicate, IL-2 increased phosphorylation on 10% of the iden-
tified phosphorylation sites and decreased 4% of the quanti-
fied phosphorylations (Figure 1D). Activation of IL-2 signaling
was verified in all three replicates by the reproducible detection
of a robust increase in phosphorylation of STAT5A pY694 and
STAT5B pY699. Western blot analysis also confirmed the IL-2
responsiveness of IL-2-deprived and IL-12-maintained CTLs,
showing strong induction of STAT5A pY694, STAT5B pY699,
and ERK1 and/or ERK2, pT202, and pY204 phosphorylations
(Figure 1E). Collectively, these experiments identified 700
phosphosites that were increased and 220 phosphosites that
were decreased in response to IL-2 stimulation of CTLs (Fig-
ure 1B). Thus, IL-2 both positively and negatively regulated pro-
tein phosphorylations in CTL.
This phosphoproteome analysis revealed that evaluating
STAT5A pY694 and STAT5B pY699 phosphorylation gives a
limited perspective of IL-2 signaling. For example, IL-2 induced
a strong Tyr phosphorylation of three adaptor proteins: GRAP2/
GADS (pY45), GAB3 (pY569), and SHC1 (pY313) (Figure 1F).
However, our dataset provided an extensive mapping of the
impact of IL-2 on the Ser/Thr phosphoproteome. For example,
phosphorylation of Ser/Thr kinases, STK17B (DRAK2) and
CAMKIV, was reproducibly increased by IL-2. The Ser phosphor-
ylation of Stathmin, a protein that controlsmicrotubule assembly,
and the actin regulator, L-plastin (LCP1), was increased with a
similar magnitude to STAT5 Tyr phosphorylation (Figure 1B and
Table S2). The functional diversity of IL-2-regulated phosphopro-
teins was striking; IL-2 equally targeted proteins linked to gene
transcription and regulators of GTPases and RNA (Figure 1G
and Table S3). Notably, the regulation of GTPase-activating
proteins (GAPs) and guanine nucleotide exchange factors
(GEFs) for Rac, CDC42, and RHO, as well as Cofilin1 and 2,
and actin (Figure 1H and Table S3) revealed that IL-2 signaled
to the actin cytoskeleton. IL-2-controlled phosphorylation of
regulators of ADP ribosylation factors (ARFs) and Ras-like pro-
teins in brain (RABs), in addition to VAMP3, DENND4C, and
EXOC7 indicated that IL-2 signaled to molecules that control
intracellular vesicle transport and exocytosis (Figure 1H).
IL-2 Regulation of the Nuclear Environment and mRNA
Translational Machinery
IL-2 controls transcriptional programs to promote CTL terminal
differentiation (Macintyre et al., 2011; Pipkin et al., 2010). In addi-
tion to the Tyr phosphorylations that promote STAT5 DNA bind-
ing, the present data showed that IL-2 controlled STAT5A S127
and S128 phosphorylation (Figure 2A). IL-2-induced Ser phos-
phorylation of STAT5 has been proposed to regulate STAT5 tran-
scriptional function (Beadling et al., 1996; Clark et al., 2005).
IL-2-regulated phosphoproteins included other transcription
factors such as MYC and NFIL3A; proteins that modify histones
and chromatin; DNA helicases; and constituents of the RNA po-
lymerase II machinery such as TAF3—a TFIID subunit—and the
RNA polymerase II subunit A C-terminal domain phosphatase,
CTDP1 (Figure 2A and Table S2). IL-2 reproducibly increased
TRIM28 S473 phosphorylation (Figure 2A). TRIM28 is a co-
repressor that mediates transcriptional silencing and is impor-
tant for T cell development and peripheral T cell homeostasis
(Chikuma et al., 2012). TRIM28 complexes with heterochromatin
Figure 1. Phosphoproteomic Analysis of IL-2 Maintained CTL
(A) Experimental workflow for SILAC-based quantitative phosphoproteomic analysis of T cells.
(B) CTLs differentiated as in (A) were starved of IL-2 for 24 hr in the presence of IL-12 to sustain expression of CD25 (IL-2 quiesced). The heavy-labeled CTLs
were stimulated with 20 ng/mL IL-2 for 15 min mixed with the control (light) cells, and phosphopeptides were prepared. Phosphosites identified in three
biological replicates are shown, with log-transformed SILAC ratios plotted against log-transformed p values (one sample t test); refer to Tables S1 and S2
for identified phosphosites. Phosphosites with ratios reproducibly changed by 1.5-fold are shown in dark gray. The 50 phosphositesmost reproducibly increased
by IL-2 are shown in red and are displayed alongside. Phosphosites found to show a statistically significant regulation (p value % 0.05) are marked with an
asterisk (*).
(C) The overlap and correlation in the SILAC ratios of the phosphosites identified in the individual biological replicates is shown.
(D) The numbers and percentages of phosphosites regulated in each replicate are shown.
(E) CTL deprived of IL-2 and maintained in IL-12 were treated with or without IL-2 for 15 min and analyzed for STAT5 and ERK phosphorylation by immunoblot.
(F) A schematic representation of the IL-2-regulated phospho-Tyr residues is shown.
(G) The proteins regulated by phosphorylation in response to IL-2 were evaluated for function. The graph shows the cluster enrichment score as determined by
DAVID analysis. See also Table S3.
(H) Overview of selected phosphosites regulated consistently by IL-2 in two or more experiments in proteins that regulate the cytoskeleton or vesicle transport.
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Figure 2. IL-2 Couples the Control of the Nuclear Environment with Translation
(A) Schematic overview of selected phosphosites in nuclear proteins regulated consistently by IL-2 in quiesced CTLs in two or more experiments.
(B) Immunoblot analysis of the phosphorylation of YBX1 in CTLs.
(C) Schematic overview of mTORC1 signaling and translational machinery proteins identified in the IL-2 dataset. Phosphosites found to show a statistically
significant regulation (p value% 0.05, one sample t test) are marked with an asterisk (*).
See also Table S2.
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protein 1 (HP1) family proteins to control chromatin remodeling;
the phosphorylation of S473 in TRIM28 inhibits HP1 binding and
co-repressor function (Chang et al., 2008). Together, these data
expose the extensive influence IL-2 may have on transcription.
Implementation of gene expression relies on mRNA transcript
processing and translation. Interestingly, IL-2 stimulated the
phosphorylation of nuclear pore proteins, including Nup98 and
Nup214, that are required for mRNA export into the cytoplasm
(Figure 2A). IL-2 also controlled phosphorylations on proteins
that direct RNA stability (Figure 2A). IL-2 stimulated phosphory-
lation of S100 in YBX1, a component of messenger ribonucleo-
protein particles (mRNPs). This phosphorylation was validated
using phospho-specific antibodies (Figure 2B). YBX1 binds to
mRNAs to prevent their association with the translation initiation
complex: phosphorylation of YBX1 on S100 blocks mRNA
binding, thereby permitting translation of YBX1 binding mRNAs
(Evdokimova et al., 2006).
Thus, the current data argue that IL-2 has the potential to co-
ordinate the composition of the nuclear proteome, the function of
the nuclear pore, and the RNA binding capability of mRNPs to
orchestrate which gene transcripts are processed into protein
in CTLs. Additionally, we noted that IL-2 regulated the phosphor-
ylation of key components of the translational machinery, e.g.,
EIF5B (Figure 2C), which is critical for translation initiation,
including stabilizing the association of the initiation methionine-
tRNA with the ribosome and regulating ribosome assembly
(Lee et al., 2014). The phosphoproteomic dataset also confirmed
previous observations that IL-2 regulates the activity of mTORC1
(Figure 2C), a kinase that controls mRNA translation and protein
degradation pathways and shapes the CTL proteome (Hukel-
mann et al., 2016).
JAK-Controlled Phosphorylation Pathways in CTLs
The Tyr kinases JAK1 and JAK3 are important for IL-2 signaling,
but their role in regulating CTL phosphoproteomes has not been
defined. Accordingly, we used SILAC-based mass spectrometry
to compare the phosphoproteome of CTLs maintained in IL-2
alone both before and after a 30-min or 4-hr treatment with the
JAK3 and JAK1 inhibitor, Tofacitinib. The ability of Tofacitinib
to inhibit JAKs was verified by its ability to cause a rapid and
sustained loss of STAT5 Tyr phosphorylation (Figure 3A). The
collective analysis of three biological replicates for the 30-min
Tofacitinib treatment identified 8,839 phosphosites on 3,086
proteins (Figure 3B and Table S4). In each replicate, Tofacitinib
decreased phosphorylation on 4% of the identified phosphor-
ylation sites (Figure S1A). It was also striking that Tofacitinib
caused an increase in 4% of the detected phosphoproteome
(Figure 3B). Collectively, these experiments identified 283 phos-
phosites that were decreased and 237 phosphosites that were
increased in response to 30 min of Tofacitinib treatment of
CTLs (Figure 3B). Following 4 hr of Tofacitinib treatment, we
identified 11,822 phosphosites in CTLs from 3,499 proteins (Fig-
ure 3C and Table S5). In total, we identified 450 downregulated
and 185 upregulated phosphorylations in the 4-hr Tofacitinib-
treated CTLs (Figure 3C).
Both datasets confirmed that Tofacitinib treatment caused a
rapid and sustained loss of STAT5A and STAT5B Tyr phosphor-
ylation but also revealed a decrease of the IL-2-regulated Tyr
phosphorylations in SHC1 (pY313) and GAB3 (pY569) (Fig-
ure 3D). The rapidity in the loss of IL-2-regulated Tyr phosphor-
ylations following JAK inhibition is consistent with high levels
and/or activity of protein Tyr phosphatases in CTLs. Additionally,
Tofacitinib treatment impacted the Ser/Thr phosphorylation
network in CTLs; the ratio of pS:pT:pY in the Tofacitinib-regu-
lated phosphosites was 35:6.5:1. Indeed, there were striking
changes to a core set of pS and pT phosphorylations at both
the 30-min and 4-hr time points (Table S6). Moreover, there
was clear reciprocal regulation of Ser/Thr phosphorylation sites
modulated by IL-2 and Tofacitinib (Figure 3E), including those
in L-plastin, Stathmin, DENND4C, and STAT5. These data indi-
cate that an IL-2-JAK1/3 pathway controlled diverse Ser/Thr ki-
nases in CTLs. In particular, the phosphoproteomics indicated
that JAKs couple IL-2Rs to regulation of mRNA stability and
translation and, hence, protein synthesis (Figure 3F), as there
was reciprocal regulation of the phosphorylation of YBX1,
LARP1, LARP4B, and EIF3A by IL-2 and Tofacitinib (Figure 3E).
We tested this hypothesis using a sensitive single-cell assay
that quantifies the catalytic incorporation of an analog of puro-
mycin, an aminoacyl-tRNA mimetic, into elongating nascent
protein chains in the ribosome. IL-2-stimulated CTLs have high
protein synthesis and a high protein content compared to
CTLs treated with Tofacitinib or CTLs cultured without cytokine
(Figures 3G and 3H). The prediction from phosphoproteomics
was thus correct: IL-2-JAK signaling pathways are essential for
protein synthesis and maintenance of CTL mass.
Evidence for Tofacitinib Insensitive IL-2 Signaling in
CTLs
Interestingly, we uncovered some discordance between the
IL-2- and Tofacitinib-regulated phosphoproteomes. Notably,
IL-2 stimulation triggered dephosphorylation of a number of pro-
teins that did not show increased phosphorylation in response to
Tofacitinib inhibition of JAK3 and/or JAK1 (Figures 4A–4C). For
instance, Cofilin, an important regulator of actin filament dy-
namics, is inactivated by S3 phosphorylation and reactivated
by S3 de-phosphorylation mediated by phosphatases such as
slingshot 1 (SSH1) (Mizuno, 2013). IL-2 stimulated dephosphor-
ylation of Cofilin S3, yet phosphorylation on this site was not
controlled by Tofacitinib (Figure 4C). Thus, IL-2 may orchestrate
Tofacitinib-independent signaling pathways. It is also possible
that there are different thresholds of JAK signaling needed for
different responses. The Tofacitinib concentrations used herein
totally blocked STAT5 phosphorylation, but it is impossible to
exclude a small pool of JAK molecules that were inaccessible
to the inhibitor. We also noted that some IL-2-regulated phos-
phorylations were only lost after sustained Tofacitinib treatment,
e.g., STAT5A Y694 was dephosphorylated within 30 min of
Tofacitinib treatment, whereas STAT5A S127 and S128 were
only decreased in the 4-hr treatment. Protein dephosphorylation
following kinase inhibition is determined by the activity of rele-
vant phosphatases. The differential kinetics of STAT5 Tyr and
Ser dephosphorylation informs about the relative abundance
and/or activity of the STAT5 Tyr and Ser phosphatases. Hence,
the finding that a significant subset of IL-2-stimulated phosphor-
ylationswas not decreased following 4 hr of Tofacitinib treatment
(Figures 4A–4C) could reflect that these are very stable modifica-
tions due to low activity and/or accessibility of the relevant
phosphatases.
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IL-2- and JAK-Independent SRCFamily KinaseSignaling
Networks in CTLs
The phosphoproteomic datasets identified 13,134 phosphosites
on 3,706 proteins in CTLs that were not modulated by IL-2 or by
Tofacitinib treatment (Table S7). The majority of these were Ser/
Thr phosphorylations but included a subset of 105 Tyr phosphor-
ylations in 93 proteins comprising adaptor proteins and enzymes
(Figure 4D). Among them were regulatory pY sites in the SRC
kinases, LCK (Couture et al., 1996; Marth et al., 1988) and FYN
(Maksumova et al., 2005); the Tec family Tyr kinases, TEC (Titz
et al., 2010) and TXK (Chamorro et al., 2001); and the pseudoki-
nase SGK223 (Safari et al., 2011) (Figure 4E). Interestingly, the
protein Tyr phosphatases, PTPN6/SHP-1 and PTPN11/SHP-2,
were phosphorylated on key regulatory sites required for their
optimal activity (Cunnick et al., 2002; Lu et al., 2001; Zhang
et al., 2003) (Figure 4E). Notably, these Tyr phosphosites showed
a strong representation of SRC family kinase consensus motifs
and sites experimentally assigned as SRC family kinase sub-
strates (Table S8). These included the regulatory phosphoryla-
tion in the activating loop of TXK/RLK (pY420) and the corre-
sponding phosphorylation in TEC (pY518) and pY170 in CD3
epsilon (de Ao´s et al., 1997). Moreover, we identified two well-
characterized SRC substrates in non-lymphoid cells: pY118 in
paxillin (Vindis et al., 2004) and pY44 in the metabolic enzyme,
enolase (Luo et al., 2008; Tanaka et al., 1995). CTLs co-express
the SRC family kinases LCK and FYN, and the phosphoproteo-
mic data revealed that these kinases were phosphorylated on
sites associated with catalytic activation: pY394 in LCK and
pY420 in FYN (Figure 4E). The SRC family kinase phosphoryla-
tion signature, particularly the activating phosphorylations of
LCK and FYN, was not regulated by IL-2 or by Tofacitinib. The
SRC kinase phosphorylation signature was identified in CTLs
maintained in IL-2 alone and also in the quiescent CTLs main-
tained in IL-12. Moreover, phosphoproteomics analysis revealed
that the SRC kinase signature was not increased by IL-12 treat-
ment of IL-2-maintained CTLs (Figure S2A). The data are consis-
tent with previous reports that SRC family kinases are constitu-
tively active in T cells (Nika et al., 2010).
To explore LCK- and/or FYN-controlled phosphorylations in
CTLs, we used the selective SRC family kinase inhibitor, PP2.
This inhibitor did not prevent IL-2 activation of JAKs, as
STAT5A Y694 and STAT5B Y699 phosphorylations were sus-
tained in IL-2-maintained CTLs following exposure to PP2
(Figure 5A). Moreover, prolonged PP2 treatment did not cause
loss of expression of CD25, a well-established JAK1/3-STAT5-
regulated protein (John et al., 1996; Kim et al., 2001; Lin et al.,
2012) (Figure 5B), nor did PP2 mimic the impact of IL-2
withdrawal on CTL size (Figure 5C) or mass (Figure 5D).
SILAC-based quantitative mass spectrometry analysis of IL-2-
maintained CTLs, both before and after treatment with PP2,
confirmed PP2 selectivity. Effective PP2 inhibition of LCK
and/or FYN was emphasized by decreased phosphorylation
of TXK/RLK pY420, Enolase pY44, paxillin pY118, SGK223
pY196, and PTPRa pY825 (Figure 5E), yet JAK1 and JAK3
signaling remained intact. PP2 treatment neither downregu-
lated STAT5A pY694 and STAT5B pY699 phosphorylation (Fig-
ure 5E) nor modulated autophosphorylation sites of JAK1
(pY1033) or JAK3 (pY781). There was also little overlap in the
Tyr phosphorylations downregulated by Tofacitinib versus
PP2 (Figure 5E). For example, PP2 treatment also did not inhibit
SHC1 pY313 Tyr phosphorylation (Figure 5E), a key step in the
activation of the Ras-ERK1 and ERK2 pathway. Indeed, PP2
treatment did not inhibit ERK1 and ERK2 phosphorylation in
IL-2-stimulated CTLs (Figure 5F).
Collectively, PP2 decreased 779 phosphorylations on 554
proteins and increased 469 phosphorylations on 349 proteins
in CTLs (Figures 5G and S2B and Table S9). The limited overlap
with the Tofacitinib-regulated phosphorylations (Figure 5H)
consisted mainly of pS and pT sites. It was notable that phos-
phoproteins reproducibly regulated by PP2 were enriched in
ATP-binding proteins, including diverse Ser/Thr kinases (Fig-
ure 5I and Table S10). This impacted signaling by protein ki-
nase C; protein kinase D2; the MAP kinase, ERK3; and the
AMP family kinases SIK1, SIK2, and SIK3 (Figure 5J). The
data also indicated that LCK- and/or FYN-mediated signaling
restrains the activity of the MAP2K4-p38-MAPKAP2 Ser/Thr ki-
nases (Figure 5J).
There were a small number of phosphorylations that were co-
regulated by IL-2-JAK1/3 and SRC kinases (Figure 6A and Table
S11). These include mTORC1-controlled phosphorylations on
ribosomal S6 proteins (Figures 6A and 6B). Flow cytometric
quantification of S6 pS235 and/or pS236 phosphorylations using
phospho-specific antibodies confirmed that IL-2-maintained
CTLs have high levels of S6 phosphorylation that are downregu-
lated in CTLs treated with either Tofacitinib, PP2, or themTORC1
inhibitor rapamycin (Figure 6C). Moreover, western blot analysis
of the phosphorylation of the mTORC1 substrate sequence on
S6K1 (pT389) confirmed that activity of both JAKs and SRC
Figure 3. Analysis of the Impact of the JAK1/JAK3 Inhibitor, Tofacitinib, on the IL-2-Maintained CTL Phosphoproteome
(A) Immunoblot analysis of the STAT5 phosphorylation in CTLs maintained in IL-2 only over a time course of treatment with 100 nM Tofacitinib, a JAK1/3 inhibitor.
(B and C) Heavy-labeled SILAC CTLs were treated with 100 nM Tofacitinib for 30 min (B) or 4 hr (C) before being mixed with control (light) CTLs for phospho-
proteome analysis. Log-transformed SILAC ratios are plotted against log-transformed p values (one sample t test). See also Figure S1, and refer to Tables S4 and
S5 for lists of phosphopeptides. The graphs in (B) and (C) show the phosphosites identified in three biological replicates. Phosphosites with ratios reproducibly
changed by 1.5-fold are shown in dark gray.
(D) The impact of Tofacitinib on the IL-2-regulated Tyr phosphorylation sites is shown.
(E) The heatmap shows phosphosites inversely regulated by IL-2 and Tofacitinib.
(F) Tofacitinib-regulated phosphorylation sites identified in proteins involved in mRNA processing, transport, stability, and translation are shown. See also
Table S6.
(D–F) Phosphosites found to show a statistically significant regulation (p value% 0.05, one sample t test) are marked with an asterisk (*).
(G) Protein synthesis of CTLs maintained in IL-2 only, or IL-2 maintained CTL treated with 100 nM Tofacitinib (Tof) or deprived of any cytokines (WO) for different
times was measured by puromycin incorporation using a flow-cytometry-based assay. Representative flow cytometry plots of the puromycin incorporation
measurements are shown, with color-matched individual replicate data from three biological replicates shown alongside. The quantified protein content, as
determined by BCA assay, of the same cells at each time point is shown in (H). Bars in (G) and (H) show the mean ± SD.
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kinases is required to sustain mTORC1 activity in CTLs (Fig-
ure 6D). Collectively, these data show that IL-2-JAK signaling
coordinates with SRC-kinase-controlled phosphorylation path-
ways to control mTORC1 activity in CTLs.
SRC Family Kinase Regulation of PIP3-AKT Signaling
Pathways in CTLs
The Ser/Thr kinase AKT plays an important role in CTLs to regu-
late nuclear exclusion and function of the FOXO1 and FOXO3
transcription factors. These simultaneously induce and repress
expression of genes encoding key effector and trafficking mole-
cules to direct effector and/or memory CD8+ T cell differentiation
(Hedrick et al., 2012). It has been proposed that the PI3K-AKT-
mTORC1 pathway is sensitive to JAK3 inhibition (Smith et al.,
2016). However, this conclusion is based on experiments with
a new JAK3 inhibitor that monitored S6 phosphorylation as a
surrogate for AKT activity (Smith et al., 2016). The present data
show that mTORC1-mediated phosphorylation of S6 in CTLs is
also Tofacitinib sensitive (Figures 6C and 6D). However, a salient
fact is that the activity of mTORC1 and the phosphorylation of
S6 are independent of AKT or PI3K in CTLs (Finlay et al., 2012;
Hukelmann et al., 2016). Therefore, to assess the effect of JAK
inhibitors on AKT activity, more direct assays and analyses are
required.
The current mass spectrometry dataset had little coverage of
AKT or AKT phosphosites reflecting biases against the detection
of the R/K-X-R/K-X-X-pS/T-4AKT substrate sequence when us-
ing trypsin for protein digestion (Giansanti et al., 2015). We did
detect one putative AKT substrate sequence, PRAS40/AKT1S1
T247 phosphorylation, which was increased following IL-2 stim-
ulation but was neither modulated by Tofacitinib nor by PP2
treatment (Figure 7A).
To explore the role of IL-2 and JAKs in controlling AKT activity
in more detail, we therefore adopted biochemical experiments.
The activity of AKT is controlled by PDK1-mediated phosphory-
lation of T308 in the AKT catalytic domain. The association
between AKT and PDK1 is facilitated both by PIP3 and the
mTORC2-mediated phosphorylation of AKT on S473 (Najafov
et al., 2012). Accordingly, we directly assessed the regulation
of AKT phosphorylation by JAK and SRC kinase pathways. IL-
2-cultured CTLs had high AKT T308 and S473 phosphorylation,
which was lost if cells were treated with the PI3K-p110d inhibitor,
IC87114, or the allosteric inhibitor, AKTi, which prevents PIP3
binding to AKT (Figure 7B). These experiments showed that
AKT activity in CTLs was dependent on sustained production
of PIP3 and sustained interaction of PIP3 and AKT. CTLs treated
with Tofacitinib lost STAT5 Tyr phosphorylation and decreased
phosphorylation of AKT S473 (Figure 7B), but there was only a
minimal effect of Tofacitinib on AKT T308 phosphorylation and
no detectable effect of Tofacitinib on the phosphorylation of
the FOXO1 pT24 and FOXO3 pT32 AKT substrate sequences
(Figure 7B). However, PP2 blocked the phosphorylation of AKT
T308 and FOXO1 pT24 and/or FOXO3 pT32 (Figure 7B). We
also found that IL-2 deprivation for 60 min resulted in complete
loss of STAT5, but not AKT phosphorylation (Figure 7C).
Hence, SRC kinases pathways, rather than IL-2-JAK signaling,
controlled AKT in CTLs. One role for AKT is to cause phosphor-
ylation-mediated nuclear exclusion of FOXO1.We used two stra-
tegies to examine the impact of JAK and SRC kinases on the
localization of FOXO1 in CTLs: microscopic analysis of intact
cells and flow cytometry analysis of purified nuclei from CTLs
expressing a FOXO1-GFP fusion protein. In IL-2-maintained
CTLs, which have high AKT activity, FOXO1-GFP was predomi-
nantly localized to the cytoplasm (Figures 7D and 7E). When
CTLs were treated with IC87114 (Figure 7F) or AKTi (Figure 7G),
the FOXO1-GFP relocated to the nucleus. The majority of
FOXO1-GFP also relocalized to the nucleus in PP2, but not
Tofacitinib-treated, CTLs (Figures 7H–7J).
As PIP3 levels are rate limiting for AKT activation, the differen-
tial sensitivity of AKT phosphorylation and activity to PP2 and
Tofacitinib raised the possibility that SRC kinases, rather than
JAK signaling, controlled PIP3 levels in IL-2-maintained CTLs.
Lipid measurements confirmed that PIP3 decreased in CTLs
following PI3K-p110d inhibition and PP2 treatment. However,
there was no discernible effect of Tofacitinib on PIP3 levels in
CTLs (Figure 7K). Importantly, cellular levels of phosphatidylino-
sitol (4,5)-bisphosphate (PIP2), the precursor of PIP3, were not
changed by the inhibitors (Figure S3). We also investigated the
IL-2 dependence of PIP3 production and noted that neither
PIP3 levels nor AKT phosphorylation rapidly declined in IL-2-
deprived CTLs (Figures 7K and 7L). Thus, IL-2R occupancy is
not tightly coupled to PIP3 production, AKT activation, or
FOXO1 phosphorylation and nuclear exclusion in CTLs. Rather,
our data support a model where IL-2-JAK signaling integrates
with IL-2-JAK-independent phosphorylation networks to pro-
gram CTL fate (Figure S3).
DISCUSSION
This study provides a systematic characterization and extensive
documentation of the IL-2-regulated phosphoproteome and an
SRC-family-kinase-controlled phosphorylation network in cyto-
toxic T cells. Our data afford new perspectives about the diverse
Ser/Thr phosphorylations controlled by IL-2 to direct T cell
biology and afford novel insights into critical signaling networks
that can modify the outcome of IL-2 signaling and control CTL
fate. We found that SRC family kinases regulated a substantial
component of the CTL phosphoproteome and regulated
Figure 4. The IL-2-Dependent and -Independent CTL Phosphoproteome
(A–C) Average SILAC ratios for 4 hr Tofacitinib treated CTLs maintained in IL-2 only were plotted against average SILAC ratios for IL-2-stimulated quiescent
(starved of IL-2 but maintained with IL-12) CTLs. All data are shown in light gray, with dark gray circles indicating the phosphorylation sites regulated by IL-2, but
not by Tofacitinib; the black circles show the phosphorylation sites inversely regulated by IL-2 and Tofacitinib; and the red points showing the phosphosites on
proteins grouped by their annotated GO functions in transcription (A), histone modification (B), or vesicle transport and the cytoskeleton (C). Selected phos-
phorylation sites regulated by IL-2, but not Tofacitinib, are shown below each graph.
(D) Schematic representation of selected Tyr phosphorylated proteins identified in quiescent and IL-2 maintained CTL that are not regulated by IL-2 or JAK1/3
inhibition. Where identified phospho-Tyr residues fit a SRC family kinase motif, the protein is shown in red. See also Table S8.
(E) The location and function of certain identified Tyr phosphorylation sites is shown.
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phosphorylations that were distinct from those modulated by
IL-2-JAK1/3. Links between SRC kinases and IL-2 signaling
were first described 25 years ago (Hatakeyama et al., 1991;
Horak et al., 1991; Kobayashi et al., 1993; Zhou et al., 2000).
We found no evidence that IL-2-JAK signaling stimulated LCK
and/or FYN kinase activity; rather, a pool of active SRC family
kinases was required to sustain the activity of critical Ser/Thr
kinases, such as mTORC1 and AKT, in IL-2-stimulated CTLs.
Figure 5. Impact of the SRC Kinase Inhibitor, PP2, on the CTL Phosphoproteome
(A) Immunoblot analysis of STAT5 pY phosphorylation in CTLs maintained in IL-2 only and treated with 10 mM PP2 or 100 nM Tofacitinib (Tof) for 1 hr.
(B) Flow cytometry analysis of the expression of CD25 in IL-2-maintained CTLs treated without or with 10 mM PP2 for 24 hr. The histogram is representative of at
least three experiments.
(C and D) CTLs differentiated in IL-2 alone were treatedwith 10 mMPP2 or deprived of IL-2 (WO) for 24 hr, and the size of the cells was evaluated by flow cytometry
and compared to IL-2-maintained controls. Representative FSC and SSC profiles are shown in (C), with mean FSC values of three color-matched biological
replicates shown alongside. The protein content of the same cells was determined by BCA assay and is shown in (D). In (C) and (D), the bars show themean ± SD.
(E andG–J) Heavy-labeled SILACCTLs differentiated andmaintained in IL-2 alonewere treatedwith 10 mMPP2 for 4 hr before beingmixedwith control (light) cells
for phosphoproteome analysis. The regulated Tyr phosphorylation sites identified in the dataset were compared to those regulated by IL-2 and/or Tofacitinib (E).
Protein names are shown in red when the identified phosphorylation site fits a SRC family kinase motif or is a known SRC family kinase substrate.
(F) The immunoblot analysis shows the impact of a 30-min treatment of 100 nMTofacitinib (Tof) or 10 mMPP2 on ERK phosphorylation in CTLmaintained only in IL-2.
(G) An overview of all the phosphosites identified in three biological replicates is displayed. Phosphosites with ratios reproducibly changed by 1.5-fold are shown
in dark gray. See also Figure S2 and refer to Tables S9 and S10 for full lists.
(H) Phosphosites regulated by 4 hr PP2 or 4 hr Tofacitinib treatment were evaluated for overlap.
(I) The proteins with phosphorylation sites reproducibly regulated by 4 hr of PP2 treatment were evaluated for function. The cluster enrichment score as
determined by DAVID analysis is shown.
(J) Schematic representations of selected pS and pT signaling pathways perturbed by PP2 are shown in (J). In (E) and (J), phosphosites found to show a
statistically significant regulation (p value% 0.05, one sample t test) are marked with an asterisk (*).
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Figure 6. Comparison of Tofacitinib- and PP2-Co-regulated Phosphosites in CTL
(A) The heat map shows phosphosites residues reproducibly identified and co-regulated after 4 hr of Tofacitinib (Tof) or 4 hr of PP2 treatment in CTLmaintained in
IL-2 alone. Phosphosites found to show a statistically significant regulation in each condition (p value% 0.05, one sample t test) are marked with an asterisk (*).
See also Table S11.
(B) Schematic representation of the mTORC1 pathway and the regulation of the phosphorylation of components by IL-2-JAK and LCK and/or FYN signaling, as
determined by the phosphoproteomic analyses.
(C) The phosphorylation status of S6, which is phosphorylated when mTORC1 is active, was quantified in CTLs maintained in IL-2 alone and treated with 100 nM
Tofacitinib, 10 mM PP2, and 20 nM Rapamycin, the mTORC1 inhibitor, using a phospho-specific antibody and flow cytometry.
(D) The phosphorylation status of themTORC1 substrate, S6K (pT389) and its substrate S6 (pS235, pS236 and pS240, pS242) was determined in IL-2-maintained
CTL by immunoblot. The data in (C) and (D) are representative of at least three experiments.
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One new insight from our data was that IL-2-JAK signaling
had a complex impact on the nuclear environment of T cells
beyond STAT5 nuclear translocation. The IL-2-JAK-regulated
CTL phosphoproteome was dominated by proteins that regu-
late RNA, the protein translational machinery, vesicular traf-
ficking, exocytosis, and the cytoskeleton. This diversity affords
an explanation for the broad role of IL-2 as a regulator of the
T cell biology. In particular, we noted that JAK activity linked
the IL-2 receptor to regulatory phosphorylations on proteins
that control mRNA stability and translation. This prompted the
experiments that revealed that IL-2 sustained mRNA translation
and protein synthesis in T cells. Thus, IL-2 can configure T cell
proteomes independently of the transcriptional program. The
ability of IL-2 to control rates of protein synthesis is a mecha-
nism to explain the documented discordance between the tran-
scriptome and proteome of IL-2-maintained CTLs (Hukelmann
et al., 2016). Moreover, our results highlight that understanding
how to manipulate IL-2 signaling for therapy needs to consider
how IL-2 controls the biosynthetic capacity of the cell. The
complexity of IL-2 signaling pathways in CTLs revealed by our
data demonstrates the need for future studies that address
the kinetics of phosphorylation events and determine if these
pathways are always coordinately regulated or whether different
thresholds of IL-2R occupancy activate different IL-2 signaling
nodes.
Another important new perspective identified in this study was
the relationship between IL-2R occupancy, JAK activity, and the
control of PIP3-AKT signaling. Understanding how T cells regu-
late PIP3-AKT signaling is important, as the strength and coordi-
nation of AKT activity is pivotal for effector T cell differentiation
(Macintyre et al., 2011) and because immune function is
impaired both by constitutive activation and by loss of PI3K-
p110d activity (Angulo et al., 2013; Lucas et al., 2014; Okken-
haug et al., 2007). Current IL-2 signal transduction models place
PIP3-AKT pathways downstream of JAKs. Our data force a
revision of this model, as we found that, in CTL, the PIP3-AKT
pathway was regulated by JAK-independent SRC-family-ki-
nase-mediated signaling. The PP2 sensitivity of cellular PIP3-
AKT signaling in CTLs suggests that IL-2-JAK signaling controls
CTL function by integrating with pathways of lipid signaling
and protein phosphorylation that are organized prior to IL-2R
occupancy. The significance of ‘‘pre-organized’’ pathways of
protein phosphorylation in T cells is increasingly recognized.
For example, LCK activity is essential for antigen receptor
signaling in T cells, yet LCK activity is constitutive and not
controlled by antigen receptor occupancy (Nika et al., 2010).
Likewise, Myc expression in IL-2-maintained CTLs is defined
by the constitutive activity of the Ser/Thr kinase GSK3 (Preston
et al., 2015), and the constitutive activity of HDAC7 Ser/Thr
kinases ensures the nuclear exclusion of this key chromatin
regulator in T cells (Navarro et al., 2011). The integration of IL-
2-JAK signaling with pre-existing phosphorylation pathways
may be a key determinant of the outcome of IL-2R occupancy
andmay explain how IL-2 can have pleotropic effects in different
T cell populations. In particular, if the ability to activate AKT re-
quires the activity of SRC family kinases, and not IL-2 regulated
JAKs, our data offer an explanation for the failure of IL-2 to acti-
vate AKT in all T cells (Bensinger et al., 2004).
In summary, our data uncovered amazing complexity of
protein phosphorylation in CTLs. It revealed a dominance of
Ser/Thr phosphorylations, but here, a proviso is that shotgun
phosphoproteomics strategies can limit the detection of low-
abundance Tyr phosphorylations. Indeed, our dataset did not
detect Tyr phosphorylations of IL-2Rb subunits or JAK1 and
JAK3 previously mapped using phospho-Tyr enrichment proto-
cols in the IL-2 dependent cell line, KIT225 (Arneja et al., 2014;
Osinalde et al., 2011, 2015). It is also important to note that
peptide identifications using SILAC require that proteolytic di-
gests produce phosphopeptides of optimal size for mass spec-
trometry sequencing (Giansanti et al., 2015). These must also
contain an arginine or lysine, as these are the residues that allow
phosphopeptide quantification in SILAC-based phosphopro-
teomics. The development of new mass spectrometry technol-
ogies and approaches may allow these limitations to be by-
passed. Thus, future screens may produce further insights
into signaling in CTL. Nevertheless, collectively, our study
mapped over 18,000 phosphorylations in CTL, revealing new
insights into the phosphorylation networks that direct the
biology of these effector cells and providing a resource for
further analyses and discovery.
EXPERIMENTAL PROCEDURES
Mice
Mice were maintained in compliance with UK Home Office Animals (Scientific
Procedures) Act 1986 in the University of Dundee. P14 T cell receptor trans-
genic mice (Pircher et al., 1989) and FOXO1-GFP mice, where GFP was fused
to the C terminus of the endogenous FOXO1 gene (Stone et al., 2015), have
been described.
Figure 7. Analysis of the PI 3-Kinase-AKT Signaling Pathway in CTL
(A) The regulation of PRAS40/AKT1S1 in CTLs as determined by SILAC phosphoproteomics.
(B and C) Immunoblot analysis of AKT phosphorylation in CTLsmaintained in IL-2 alone and treated for 1 hr with 10 mMPP2, 100 nMTofacitinib, 10 mM IC87114, a
PI3K-p110d inhibitor, or 1 mM AKTi, an AKT inhibitor (B) and in response to 1 hr IL-2 deprivation (C).
(D–J) IL-2-maintained CTLs were generated from FOXO1-GFP mice. The localization of FOXO1-GFP (green) was visualized by microscopy (D), with the actin
cytoskeleton detected using phalloidin (red). The scale bar is 5 mm. FOXO1-GFP levels in nuclear extracts of IL-2-maintained CTLs were quantified by flow
cytometry under basal conditions (IL-2) and compared to a non-FOXO1-GFP-expressing CTL (WT) (E) or following 1 hr treatment with IC87114 (F), AKTi (G), PP2
(H), or Tofacitinib (Tof) (I). Representative flow cytometry profiles are shown in (F–I), with the level of FOXO1-GFP in each condition expressed as a ratio of theMFI
of the IL-2 control of eight color-matched biological replicate treatments shown in (J), with bars showing the mean ± SD.
(K and L) The levels of PIP3 in CTLs maintained in IL-2 only, shown as a ratio of the measured PIP2, were determined using mass spectrometry. In (K), IL-2-
maintained CTLs were treated with 100 nM Tofacitinib (Tof), 10 mM PP2, 10 mM IC87114, or deprived of IL-2 (WO) for 30 min and compared to IL-2-maintained
CTL control cells. In (L), PIP3 levels were measured in CTL maintained in medium alone (WO) and were compared to control (IL-2) and IL-2 + IC87114-treated
cells for up to 2.5 hr. In (K) and (L), the left-hand panels show the data for a single experiment, with the immunoblot analysis of the phosphorylation of AKT
on pT308 and pS473 shown in the middle panel. The right panel shows the results for color-matched biological replicates, 6 in (K) and 4 in (L). Bars show the
mean ± SD.
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Cell Culture and SILAC Labeling
Cytotoxic T Lymphocytes were generated as previously described (Hukel-
mann et al., 2016; Navarro et al., 2011, 2014) and expanded in RPMI 1640
medium (Life Technologies) supplemented with 10% FBS (Life Technologies),
50 units/mL penicillin-G, 50 mg/mL streptomycin, and 50 mM b-mercaptoetha-
nol and in the presence of 20 ng/mL IL-2 alone (Proleukin, Novartis). For SILAC
labeling, CTLs were cultured for 5 days in SILAC RPMI 1640 medium (Life
Technologies), supplemented with 200 mg/L L-proline, 84 mg/L L-arginine,
300 mg/L L-glutamate, 10% dialyzed FBS with a 10 kDa cutoff (Thermo Scien-
tific), 50 units/mL penicillin-G, 50 mg/mL streptomycin, 50 mM b-mercaptoetha-
nol, and 20 ng/mL IL-2. The ‘‘light’’ SILAC media contained L-[12C6, 14N4]
arginine (R0) and L-[12C6, 14N2]lysine (K0). The ‘‘heavy’’ media contained
L-[13C6, 15N4]arginine (R10) and L-[13C6, 15N2]lysine (K8).
For the IL-2 stimulation of CTLs, cells were ‘‘IL-2 quiesced’’ by the removal
of IL-2 for 24 hr, but they were supplemented with 20 ng/ml IL-12 (R&D Sys-
tems) to sustain cell viability (at90%) and the expression of the IL-2Ra chain
(CD25). For the Tofacitinib and PP2 studies, CTLs were maintained only in the
presence of IL-2, and no IL-12 was added to the culture.
Phosphoproteome Analysis
Sample preparation was performed as described in the Supplemental Exper-
imental Procedures. Three independent biological replicate treatments were
performed for each phosphoproteome analysis. The resultingmass spectrom-
etry data were processed using MaxQuant version 1.5.0.0 (Cox and Mann,
2008) and mapped to the reviewed UniProtKB-Swiss-Prot mouse protein
database. The output from MaxQuant was filtered to remove known contam-
inants and reverse sequences before analysis. The distribution of SILAC ratios
was normalized within MaxQuant at the peptide level so that the median of
Log2 ratios was zero. Perseus software was used to annotate phosphosites,
and the clustering tool in DAVID bioinformatics resources was used for func-
tional annotation.
Flow Cytometry Analysis of Nuclear Extracts
Cells (13106) were treated with 300 mL ice-cold nuclear extraction buffer
(3.8mM trisodium citrate, 9.6mMNaCl, 0.05%NP-40), and the resulting nuclei
were fixed immediately with ice-cold 300 mL IC fixation buffer (eBiosciences)
for 15 min at 4C. After washing, nuclei were stained with DAPI and analyzed
using a fluorescence-activated cell sorting (FACS) LSRFortessa flow cytome-
ter with DIVA software (BD Biosciences). Data analysis was performed with
FlowJo software (Treestar).
Analysis of Protein Synthesis and Cellular Protein Mass
Cells were treated with O-propargyl-puromycin (OPP, Jena Bioscience) for
10 min, and the incorporation of the aminoacyl-tRNA mimetic into newly syn-
thesized polypeptides was measured by labeling the OPP was with Alexa
647-azide (Invitrogen) using a standard Click-IT chemistry reaction (Invitro-
gen). Cells were analyzed using a FACSVerse flow cytometer with FACSuite
software (BD Biosciences) and analyzed with FlowJo software (Treestar).
The protein mass of cells following different treatments was determined by
BCA assay as per manufacturer’s instructions (Pierce).
Mass Spectrometry Measurements of Inositol Lipids
Inositol lipidmeasurementswereperformedbymassspectrometryusing13106
cells per sample as described in the Supplemental Experimental Procedures.
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